Table 2.
Serology panel information.
| ID | Virus | DPI | Dilution | ASF ELISA Kit #1 | ASF ELISA Kit #2 | IPT | CSF ELISA | Conclusion |
|---|---|---|---|---|---|---|---|---|
| Sample 1 | ASFV Georgia 2007/1. P110 | 16 | 1/20 | 16.63 | 8.26 | Neg | −1.6 | Neg for anti-ASFV & CSFV Abs |
| Sample 2 | ASFV OURT88-3/Malta’78. P2 | 56–27-8 | 1/20 | 95.65 | 73.59 | Pos | −1.05 | Pos for antibodies to ASFV |
| Sample 3 | ASFV OURT88-3/Malta’78. P1 | 56–27-8 | 1/20 | 98.91 | 86.07 | Pos | −13.36 | Pos for antibodies to ASFV |
| Sample 4 | CSFV Suvaxyn. P10 (NPLA titer: 320) | 31 | 1/20 | 2.9 | 4.52 | Neg | 51.94 | Pos for antibodies to CSFV |
| Sample 5 | ASFV GUS Vietnam/Georgia 2007/1. P3 | DPC 21 | 1/20 | 96.05 | 77.45 | Pos | −3.18 | Pos for antibodies to ASFV |
| Sample 6 | CSFV Kanagawa. P1 (NPLA titer: 1280) | 52 | 1/20 | 3.92 | 5.55 | Neg | 87.41 | Pos for antibodies to CSFV |
| Sample 7 | Normal Pig Serum | NA | Undiluted | 6.84 | 3.78 | Neg | 2.35 | Neg for anti-ASFV & CSFV Abs |
| Sample 8 | CSFV Parma. P19-S-5 | 26 | 1/20 | 0.53 | 1.64 | Neg | −8.61 | Neg for anti-ASFV & CSFV Abs |
| Sample 9 | ASFV GUS Vietnam/Georgia 2007/. P4 | DPC 21 | 1/20 | 100.53 | 69.47 | Pos | −1.74 | Pos for antibodies to ASFV |
| Sample 10 | Hyperimmune serum CSFV. P-03-04. (NPLA titer: 5120) | NA | 1/20 | 8.06 | 7.41 | Neg | 94.02 | Pos for antibodies to CSFV |
| Sample 11 | ASFV Malta’78. P56 | 18 | 1/20 | 68.08 | 95.5 | Pos | 0.17 | Pos for antibodies to ASFV |
| Sample 12 | CSFV Brazil. P5 (NPLA titer: 640) | 34 | 1/20 | 7.59 | 5.88 | Neg | 63.37 | Pos for antibodies to CSFV |
| Sample 13 | ASFV Estonia/2014. P4 | 11 | 1/20 | 71.97 | 56.63 | Pos | 4.28 | Pos for antibodies to ASFV |
| Sample 14 | ASFV OURT88-3/Malta’78. P4 | 56–27-8 | 1/20 | 97.54 | 90.36 | Pos | 6.94 | Pos for antibodies to ASFV |
| Sample 15 | BDV I-121. P13 (NPLA titer: 640) | 48–15 | 1/20 | 7.72 | 5.38 | Neg | 13.46 | Neg for anti-ASFV & CSFV Abs |
| Sample 16 | ASFV GUS Vietnam/Georgia 2007/. P2 | DPC 21 | 1/20 | 100.1 | 63.06 | Pos | 3.81 | Pos for antibodies to ASFV |
| Sample 17 | CSFV Suvaxyn. P11 (NPLA titer: 80) | 31 | 1/20 | 0.41 | 4.18 | Neg | 40.08 | Pos for antibodies to CSFV |
| Sample 18 | ASFV OURT88-3/Malta’78. P3 | 56–27-8 | 1/20 | 98.31 | 78.17 | Pos | 5.68 | Pos for antibodies to ASFV |
| Sample 19 | ASFV Malta’78. P51 | 18 | 1/20 | 50.66 | 86.33 | Pos | 2.61 | Pos for antibodies to ASFV |
| Sample 20 | BVDV NADL. Pig 26 (NPLA titer: 1280) | 141 | 1/20 | 0.28 | 4.63 | Neg | 4.49 | Neg for anti-ASFV & CSFV Abs |
The serology panel was prepared from sera obtained from domestic pigs infected with multiple strains of ASFV, CSFV, BDV, or BVDV and tested with INGEZIM PPA COMPAC Kit (ASF ELISA kit #1), ID Screen ASF Indirect Kit (ASF ELISA kit #2), IPT, NPLA, and IDEXX CSFV Antibody Test kit (CSF ELISA). Result interpretation: X% ≥ 50%, positive; X% X < 40%, negative; 50% > x% ≥ 40%, suspicious (ASF ELISA kit #1). S/p ≥ 40%, positive; S/p ≤ 30%, negative; 30% < S/p < 40%, suspicious (ASF ELISA kit #2). X% ≤ 30%, negative; > 30 to <40%, suspicious; ≥ 40%, positive (CSF ELISA). Bold, ASF-positive; italic, CSF-positive; DPI, days post-inoculation; DPC, days post-challenge; Neg, negative; Pos, positive.